Results 131 to 140 of about 4,742,503 (345)

Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47

Cancer Communications, EarlyView.
Abstract Background Only a few bladder cancer patients benefit from anti‐programmed cell death protein 1/programmed cell death ligand 1 immunotherapy. The cluster of differentiation 47 (CD47) plays an important role in tumor immune evasion. CD47 is a highly glycosylated protein, however, the mechanisms governing CD47 glycosylation and its potential ...
Jie Zhang, Chen Zhang, Ruichen Zang, Weiwu Chen, Yining Guo, Haofei Jiang, Jing Le, Kunyu Wang, Haobo Fan, Xudong Wang, Sisi Mo, Peng Gao, Wenhao Guo, Xinrong Jiang, Fengbin Gao, Junming Jiang, Juyan Zheng, Yuxing Chen, Yicheng Chen, Yanlan Yu, Guoqing Ding   +20 more
wiley   +1 more source

Evaluation of the reproducibility of the revised 1988 international federation of gynecology and obstetrics grading system of endometrial cancers with special emphasis on nuclear grading [PDF]

, 1991
Anette Lynge Nielsen, Henrik Klem Thomsen, Henrik Christian Juul Nyholm   +2 more
openalex   +1 more source

Short‐chain acyl post‐translational modifications in cancers: Mechanisms, roles, and therapeutic implications

Cancer Communications, EarlyView.
Abstract Post‐translational modifications (PTMs) play a pivotal role in epigenetic regulation and are key pathways for modulating protein functionality. PTMs involve the covalent attachment of distinct chemical groups, such as succinyl, crotonyl, and lactyl, at specific protein sites, which alter protein structure, function, stability, and activity ...
Ting Wu, Yingqi Zhao, Xin Zhang, Yuanhe Wang, Qiuchen Chen, Mingrong Zhang, Huan Sheng, Yuying Zhang, Jinyu Guo, Jun Li, Yuxuan Fan, Ziqing Wang, Yalun Li, Haoran Wang, Minjie Wei, Xiaoyun Hu, Huizhe Wu   +16 more
wiley   +1 more source

Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study

Cancer Communications, EarlyView.
Abstract Background Cadonilimab is a humanized immunoglobulin G1 bispecific antibody targeting programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4). This study aimed to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) combined with cadonilimab in patients with advanced recurrent or ...
Yao Xiao, Yuxia Wang, Jun Li, Cheng Cheng, Chunyong Song, Xin Wang, Liyuan Tao, Hongqing Zhuang   +7 more
wiley   +1 more source

Family History of Breast, Ovarian and Endometrial Cancer and Risk of Breast Cancer [PDF]

, 1993
Fabio Parazzini, Carlo La Vecchia, Eva Negri, Silvia Franceschi, Luca Tozzi   +4 more
openalex   +1 more source

Lactylation in cancer biology: Unlocking new avenues for research and therapy

Cancer Communications, EarlyView.
Abstract Lactylation, a newly identified post‐translational modification, plays a multifaceted role in cancer biology by integrating epigenetic and non‐epigenetic mechanisms. This review summarizes the latest research progress on lactylation, including its functions in epigenetic regulation and its broader impact on cellular processes.
Xiaoyu Hou, Zhenya Hong, Huimin Zen, Changyi Zhang, Peng Zhang, Ding Ma, Zhiqiang Han   +6 more
wiley   +1 more source

The use of endocervical and endometrial smears in the diagnosis of cancer and of other conditions of the uterus

, 1943
George N. Papanicolaou, Andrew A. Marchetti   +1 more
openalex   +1 more source

Identification of Anoikis‐Related Subgroups and Prognosis Model in Colon Cancer

Cancer Nexus, EarlyView.
ABSTRACT Background Anoikis represents a distinct type of programmed cell death that serves a critical function in tumor development and metastatic. Despite its significance, there remains a notable gap in comprehensive studies that explore the role of Anoikis specifically within the context of colon cancer (CC). Thus, it becomes imperative to pinpoint
Shaokang Yang, Peng Yang, Zhicheng Liu, Yujia Chen, Qitong He, Daguang Wang   +5 more
wiley   +1 more source

Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open‐Label Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Imlunestrant (LY3484356) is a next‐generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor–positive advanced breast and endometrial cancers. This Phase 1, open‐label, 2‐part study evaluated the disposition and absolute bioavailability of [14C]‐imlunestrant in 16 US‐based ...
Amita Datta‐Mannan, Boris Czeskis, Elaine Shanks, Eunice Yuen, Stephen Hall, Vivian Rodriguez Cruz, Kenneth Cassidy   +6 more
wiley   +1 more source

Endometrial carcinoma with trophoblastic differentiation. An aggressive form of uterine cancer [PDF]

, 1991
Carlo Pesce, Maria J. Merino, Joe T. Chambers, Francisco F. Nogales   +3 more
openalex   +1 more source